LLibera Bio
Libera Bio is a biopharmaceutical company developing a new class of cancer therapeutics that reach 'undruggable' intracellular targets, built on its proprietary MPN Technology (Multifunctional Polymeric Nanoparticles) that protects whole antibodies, nanobodies, small molecules and PROTACs in the bloodstream and delivers them inside tumour cells. A 2020 spin-off of the University of Santiago de Compostela out of Prof. Maria Jose Alonso's nanomedicine lab, it is seed-stage and focused on KRAS-mutant cancers such as pancreatic ductal adenocarcinoma, with partnerships including ImmunoPrecise Antibodies and EVQLV. It is headquartered in Santiago de Compostela (Galicia) with a US office in Larchmont, New York.
SectorsBiotech, Oncology, Nanomedicine, Drug Delivery, Pharmaceuticals, Deeptech
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
D
Desiree Teijeiro Osorio
Co-Founder & Chief Operating Officer
O
Olivier R. Jarry
Co-Founder & CEO
Global models 5
CCapstan Therapeutics
United States · capstantx.com ↗
Platform biotech built on proprietary targeted nanoparticle delivery that gets therapeutic cargo into specific cells, monetised through its own pipeline and a pharma exit (acquired by AbbVie).
$340MComparable
RReCode Therapeutics
United States · recodetx.com ↗
Venture-backed drug-delivery platform company using proprietary lipid nanoparticles to carry therapeutics into target cells, advancing its own pipeline and partnering the platform.
$340MComparable
AAera Therapeutics
United States · aeratx.com ↗
Builds a proprietary nanoparticle delivery technology to carry large-molecule medicines into cells, the same delivery-platform-first biotech model as Libera Bio's MPN.
$193MComparable
EEntrada Therapeutics
United States · entradatx.com ↗
Its proprietary platform delivers biologics and oligonucleotides to intracellular targets, the 'undruggable inside the cell' model Libera Bio pursues, funded by VC and pharma partnerships before its IPO.
$175MComparable
B
BIND Therapeutics
United States
Polymeric nanoparticle (Accurins) cancer therapeutics company that paired an in-house oncology pipeline with platform deals with pharma, the closest precedent to Libera Bio's polymer-nanoparticle oncology model.
$140MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 8
Open as list →
XXesGalicia
www.xesgalicia.gal
CCentro para el Desarrollo Tecnológico y la Innovación
www.cdti.es
NNowture
I
Iñaki Berenguer
M
Manuel Francisco Rañal Loureiro
R
ROSP Corunna Participaciones Empresariales
S
Semola Tech Ventures
U
Unixest (Sociedade Xestora de Intereses da USC)
Funding rounds 2
News 6
Open as list →| Published | Article |
|---|---|
| 2025-11-06 |
Galician biotech companies CZ Vaccines, Libera Bio, BFlow, SunRock Biopharma and Linknovate are attending Bio-Europe 2025 in Vienna to reinforce their commitment to the European Union market ↗
Bioga
2025-11-06 |
| 2025-10-23 |
Banco Santander delivers the Santander X Spain Awards 2025 to nine innovative business ideas with high potential ↗
Capital & Corporate / Capital-Riesgo.es
2025-10-23 |
| 2025-06-10 |
Libera Bio: la revolución contra el cáncer salida de la USC ↗
El Correo Gallego
2025-06-10 |
| 2025-04-21 |
La startup gallega Libera Bio logra 1,3M€ en una ronda de inversión ↗
El Referente
2025-04-21 |
| 2024-11-25 |
Libera Bio has been selected by NYU Stern School of Business to join the prestigious New York-based mentorship program "Endless Frontier Labs" ↗
Libera Bio (press release)
2024-11-25 |
| 2024-04-23 |
Five Galician biotechs attend 'Swiss Biotech Day' with Bioga to explore ways of collaborating with the Swiss biotech ecosystem ↗
Bioga
2024-04-23 |